National Cancer Institute (Lithuania), Lithuanian Society of Oncology and Medical Faculty of Vilnius University in collaboration with Medical University of Bialystok, Mannheim University, Euroregional Medical Centre for Research, Education Lithuanian Society of Pulmonology and IASLC
| 07:00-08:00 | Registration |
|---|---|
| 08:00-08:30 | Welcome address |
| 1. Vice Minister of Health of the Republic of Lithuania 2. Adviser to the Prime Minister on Healthcare and People with Disabilities 3. Dean of the Faculty of Medicine Vilnius University 4. Director of National Cancer Institute 5. Director of Lithuanian Cancer Patients Coalition „POLA“ |
| 08:35-09:35 | Epidemiology/ Tobaco Control/ Lung Cancer Screening Chairs: Giedrė Smailytė (Vilnius, Lithuania), Vaida Gedvilaitė (Vilnius, Lithuania) |
| 08:35-08:50 | Lung Cancer: Epidemiology, Etiology, and Prevention | Giedrė Smailytė Vilnius, Lithuania | Participation Onsite |
| 08:50-09:05 | Tobaco control- Bulgarian experience | Rossitza Krasteva Sofia, Bulgaria | Participation Remotely |
| 09:05-09:20 | Lung Cancer Screening – current status and how technology will help | Wieland Voigt Erlangen, Germany | Participation Remotely |
| 09:20-09:35 | Lung Cancer Screening in China | Yao Zhang | Participation Remotely |
| 9:40-10:35 | Pathology/ Molecular Diagnostics Chairs: Kęstutis Sužiedelis (Vilnius, Lithuania) |
| 09:40-9:55 | News from the WHO Classification of Lung Neuroendocrine Neoplasms | Mauro Papotti | Participation Remotely |
| 9:55-10:10 | Can lung cancer patients benefit from genomic profiling of tumor? | Marcin Moniuszko Bialystok, Poland | Participation Remotely |
| 10:10-10:35 | Molecular profiling of Lung Cancer | Sonata Jarmalaitė Vilnius, Lithuania | Participation Onsite |
| 10:40-11:40 | Satellite MSD Chair: Edvardas Danila (Vilnius, Lithuania) |
| 10:40-11:40 | The importance of immunotherapy in first line metastatic NSCLC: optimizing survival and response |
Antti Jekunen Vaasa, Finland | Participation Remotely |
|
11:45-12:05 | Coffee break |
| 12:05-12:50 | Surgery for Lung Cancer Chairs: Miroslaw Kozlowski (Bialystok, Poland), Saulius Cicenas (Vilnius, Lithuania) |
| 12:05-12:20 | Lung cancer surgery in Covid-19 era | Miroslaw Kozlowski Bialystok, Poland | Participation Onsite |
| 12:20-12:35 | Transcervical approach for operation of various thoracic diseases | Marcin Zielinski Zakopane, Poland | Participation Remotely |
| 12:35-12:50 | Lung Cancer as Second Primary Disease | Sigitas Zaremba | Participation Onsite |
| 12:55-13:55 | Lunch |
| 13:55-14:55 | Satellite Astra Zeneca Chair: Saulius Cicėnas (Vilnius, Lithuania) |
| 13:55-14:55 | Precision medicine in non-small lung cancer, with emphasis on modern EGFR-directed therapy | Odd Terje Brustugun | Participation Remotely |
| 14:50-15:20 | Medical Management of Lung Cancer Chairs: Jacek Niklinskij (Bialystok, Poland), Edvardas Danila (Vilnius, Lithuania) |
| 14:50-15:05 | Systemic therapy for advanced NSCLC without oncogenic drivers | Sofia Baka Athens, Greece | Participation Remotely |
| 15:05-15:20 | Systemic therapy of operable NSCLC | Robert Pirker Vienna, Austria | Participation Onsite |
| 15:25-16:10 | Satellite Bristol-Myers Squibb |
| Introduction: Immunotherapy in lung cancer | Marius Žemaitis | Participation Remotely | |
| | Synchronous lung and laryngeal cancer - Case report |
Laura Norkienė Vilnius, Lithuania | Participation Onsite |
| Immunotherapy in Advanced Non-small Cell Lung Cancer Patient: case report | Jurgita Matulionė | Participation Remotely |
| 16:15-16:45 | Satellite Roche |
| 16:15-16:45 | Immunotherapy in Small Cell Lung Cancer | Marius Žemaitis | Participation Remotely |
| 16:50-17:15 | Coffe break |
| 17:15-17:45 | Satellite Pfizer Chair: Vincas Urbonas (Vilnius, Lithuania) |
| 17:15-17:45 | Treatment Sequencing in Patients with ALK-positive advanced Non-Small Cell Lung Cancer: proven benefit of third-generation ALK TKI | Saulius Cicėnas | Participation Onsite |
| 17:50-18:35 | Immuno-oncology and TKI inhibitors in Lung Cancer Chair: Christian Manegold (Mannheim, Germany) |
| 17:50-18:05 | Role of Ret targeting agents in the medical management of advanced NSCLC | Christian Manegold | Participation Onsite |
| 18:05-18:20 | Study design concepts in times of Met and Ret targeting therapies | Lothar Richard Pilz Mannheim, Germany | Participation Remotely |
| 18:20-18:35 | Imunotherapy role in lung cancer treatment | Vaida Gedvilaitė Vilnius, Lithuania | Participation Onsite |
| 18:40-19:25 | Young Investigators |
| 18:40-18:55 | Hospital-integrated biobanking as the foundation of precision medicine | Anna Michalska-Falkowska | Participation Onsite |
| 18:55-19:10 | Deciphering long non-coding RNA in non-small-cell lung cancer: the dark matter matters | Anetta Sulewska | Participation Onsite |
| 19:10-19:25 | Evaluation of CD8 + Lymhocyte Filtering non-small-cell lung cancer by digital immunohistochemistry | Jaroslavas Bublevič Vilnius, Lithuania | Participation Remotely |
| 19:30 | Closing Remarks |
| 19:50 | Dinner |